Citigroup
CRBP icon

Citigroup’s Corbus Pharmaceuticals CRBP Stock Holding History

Citigroup’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Buy
16,708
+11,454
+218% +$96.4K ﹤0.01% 4094
2025
Q4 		$42.8K Buy
+5,254
New +$64.8K ﹤0.01% 4628
2025
Q3 		– Sell
-1,657
Closed -$11.4K – 6123
2025
Q2 		$11.4K Sell
1,657
-6,641
-80% -$48.2K ﹤0.01% 5166
2025
Q1 		$44.1K Sell
8,298
-912
-10% -$8.05K ﹤0.01% 4908
2024
Q4 		$109K Buy
9,210
+1,726
+23% +$28.9K ﹤0.01% 4796
2024
Q3 		$154K Buy
7,484
+3,101
+71% +$159K ﹤0.01% 4530
2024
Q2 		$198K Sell
4,383
-10,924
-71% -$459K ﹤0.01% 3876
2024
Q1 		$601K Buy
15,307
+14,741
+2,604% +$363K ﹤0.01% 3442
2023
Q4 		$3.42K Buy
+566
New +$3.04K ﹤0.01% 5371
2021
Q4 		– Sell
-3
Closed – – 5856
2021
Q3 		$0 Sell
3
-384
-99% -$15.1K ﹤0.01% 5829
2021
Q2 		$21K Sell
387
-169
-30% -$9.38K ﹤0.01% 5265
2021
Q1 		$33K Sell
556
-505
-48% -$33.2K ﹤0.01% 4944
2020
Q4 		$40K Sell
1,061
-1,124
-51% -$42K ﹤0.01% 6194
2020
Q3 		$118K Sell
2,185
-536
-20% -$97.1K ﹤0.01% 4985
2020
Q2 		$685K Buy
2,721
+524
+24% +$106K ﹤0.01% 3933
2020
Q1 		$345K Sell
2,197
-953
-30% -$161K ﹤0.01% 4218
2019
Q4 		$516K Buy
3,150
+1,723
+121% +$255K ﹤0.01% 4396
2019
Q3 		$208K Sell
1,427
-104
-7% -$18.1K ﹤0.01% 5121
2019
Q2 		$318K Sell
1,531
-443
-22% -$94.8K ﹤0.01% 4869
2019
Q1 		$411K Buy
1,974
+103
+6% +$22.7K ﹤0.01% 4388
2018
Q4 		$329K Sell
1,871
-199
-10% -$39.7K ﹤0.01% 4542
2018
Q3 		$469K Buy
2,070
+594
+40% +$96K ﹤0.01% 4362
2018
Q2 		$224K Buy
1,476
+343
+30% +$62.3K ﹤0.01% 4944
2018
Q1 		$207K Buy
1,133
+392
+53% +$88K ﹤0.01% 4933
2017
Q4 		$158K Buy
741
+656
+772% +$140K ﹤0.01% 5259
2017
Q3 		$18K Buy
85
+75
+750% +$14.7K ﹤0.01% 6470
2017
Q2 		$2K Sell
10
-43
-81% -$8.43K ﹤0.01% 6970
2017
Q1 		$13K Buy
+53
New +$13K ﹤0.01% 6457

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup's CRBP Position: Q1 2026 in Review

Citigroup increased its Corbus Pharmaceuticals (CRBP) stake by 218% in Q1 2026, buying an estimated $96.4K and bringing the position to 16,708 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #4094.

Citigroup first reported a position in CRBP in Q1 2017 and has held it in 28 quarters since. The position peaked at $685K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Citigroup held 16,708 shares of Corbus Pharmaceuticals worth $157K as of Q1 2026.
  • Citigroup bought 11,454 Corbus Pharmaceuticals shares in Q1 2026, an estimated $96.4K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4094 holding.
  • Citigroup first reported a position in Corbus Pharmaceuticals in Q1 2017 and has held it in 28 quarters since.
  • Citigroup's Corbus Pharmaceuticals position peaked at $685K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.